Clinical

The authors developed and validated an accurate, well-calibrated, easy-to-implement COVID-19 hospitalized patient deterioration index to identify patients at high or low risk of clinical deterioration.

Trajectory of patient outcomes for those diagnosed with bronchiectasis is explored by Dr Metersky.

Clostridioides difficile risk is significantly higher in Korean patients with inflammatory bowel disease (IBD), which is comparable to the trend observed in Western patients with IBD.

A panel of medical experts discuss the shift from intervention to prevention in the management of dry eye disease, as well as perspectives on resource allocation.

Experts provide a perspective on disparities in accessibility and outcomes based on the current socioeconomic landscape in health care.

More than 15.3 million Americans enrolled in health insurance under the Affordable Care Act for 2024, which is a 33% increase from last year; emergency contraception sales in the United States may spike by around 10% in the new year; top Biden administration officials met with prominent civil rights and public health leaders on Tuesday amid the decision to delay the menthol cigarette ban.

An in-depth look into what the drug is being used for and what has contributed to the shortage.

Mark A. Socinski, MD, executive director at AdventHealth Cancer Institute, discussed the emergence of targeted therapies for lung cancer and their ongoing impact on outcomes for certain patients.

Jun Gong, MD, of Cedars-Sinai Medical Center, discusses the latest data on adagrasib in colorectal cancer, the importance of conducting genomic testing, and more.

Patients with immune-mediated thrombotic thrombocytopenic purpura (TTP) were found to have white matter damage in the frontal lobe and cingulate cortex that could affect short-term memory and depressive scores.

Patients with colorectal cancer (CRC) had reduced readmissions when treatment focused on preventing prolonged ileus, increasing the use of minimally invasive surgery, and preventing anastomotic leaks.

Coverage from The US Oncology Network Payer Transformation Summit, held September 27-29, 2023, in Atlanta, Georgia.

Experts discuss evolving strategies in ER+/HER2– metastatic breast cancer treatment, combining endocrine and targeted therapies, and leveraging specific mutations for optimal patient outcomes.

Key opinion leaders open a discussion surrounding CLL and SLL, and describing unique characteristics of each disease state.

Richard Adler, MD, FACS, Assistant Professor of Ophthalmology at the Wilmer Eye Institute, Johns Hopkins Institute, and Director of Ophthalmology Services at Belcara Health, discusses the critical unmet needs in Dry Eye Disease (DED) therapies and explores the potential impact of new agents in addressing these challenges.

Medical professionals discuss strategies and best practices for recognizing and mitigating immunotherapy toxicities through multidisciplinary collaboration and use of monitoring technology.

Real-world data presented at the 2023 American Society of Hematology Annual Meeting and Exposition showed similar toxicity profiles and outcomes among older and younger patients with multiple myeloma (MM) treated with teclistamab.

The panel emphasizes the role of multidisciplinary tumor boards in optimizing oncology care in nonmelanoma skin cancers.

This year’s most-read respiratory articles explored a variety of topics, including the effects of marijuana and vaping on the lungs.

Understanding these relationships is crucial for developing effective clinical management strategies for patients with AD, according to a recent literature review.

The FDA approved the first test to assess opioid addiction risk; Americans are using more cold and allergy medicines to mask any related symptoms to return to work and social gatherings, but may be overtreating themselves in the process; Rite Aid will be banned from using artificial intelligence–powered facial recognition technology for 5 years under a proposed Federal Trade Commission settlement.

Increased pulmonary arterial hypertension (PAH) awareness and earlier screening in routine clinical practice could provide an opportunity for earlier treatment, resulting in reduced economic burden for payers, employers, and society at large.

Bio-Thera Solutions’ Avzivi (bevacizumab-tnjn) has become the fifth biosimilar referencing Avastin (bevacizumab) to be approved in the United States.

Therapeutic and financial considerations of EVT are explored by a medical expert.

An expert panel unpacks challenges in implementing bispecific therapies for operational excellence.